FDA rejects TransEnterix's SurgiBot marketing application; shares down 54%

|By:, SA News Editor

TransEnterix (TRXC -54.2%) plummets on a 6x surge in volume in response to its announcement that the FDA has rejected its 510(k) application seeking clearance of its SurgiBot System. Under the 510(k) process, a company only has to demonstrate substantial equivalence to a product that is already cleared for sale in the U.S.

The company will update investors on the situation during its earnings call on May 10 after the close.

Subscribe for full text news in your inbox